Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Simponi (Golimumab) – Treatment for Ulcerative Colitis (UC)

Drug Name (Brand / Generic)

Simponi / golimumab

Company / Licensee

Janssen Biotech

Therapy Class

Anti-tumour necrosis factor (TNF)-alpha therapy

Product Description

Human monoclonal antibody

Current Indication

Moderately to severely active ulcerative colitis (UC)

Development Status

Approved in the US

Market Sector

Gastroenterology
Expand
Close
Close
Close

Go Top